About

Chugai Group’s mission is to create innovative drugs for the benefit of patients.

Message from the CEO

Hideaki Shimada PH.D.

Director, Chief Executive Officer

In the global medical field, many diseases such as cancer, inflammatory diseases, and metabolic diseases still lack drug treatments or have existing drugs which do not sufficiently address the medical needs of patients. A subsidiary of Chugai Pharmaceutical, a member of the Roche group, Chugai Pharmabody Research (CPR) aims to pioneer new frontiers in drug discovery to solve these unmet needs.

Leveraging on our world-leading proprietary antibody engineering and cyclic peptide technology, we focus on innovative drug development that can move the needle and deliver better clinical outcomes for patients. These novel technologies enable us to expand druggable targets and invent unique therapeutic actions to meet unsatisfied clinical needs. Our cutting-edge technologies have allowed us to achieve a competitive advantage in the highly intensive field of drug discovery.

Tapping on Singapore’s holistic science ecosystem for world-class biomedical research, CPR is able to draw on Singapore’s strong infrastructure, a highly-trained pool of multinational scientists and supportive government policies to establish our highly-sophisticated antibody and cyclic peptide drug discovery platforms.

By working as a unified team and building upon our R&D investments, resources and talent, we have positioned ourselves as a global leader in antibody and cyclic peptic drug discovery research. We aspire to translate advanced science and technologies into revolutionary antibody and cyclic peptide drugs that can significantly improve patients’ lives and make a positive contribution to the global medical community.

OUR VISION

We aim to create innovative drug against the disease with high unmet medical needs for the human health around the world.

We will become a top innovator to realise advanced and sustainable patient-centric healthcare by our unique strength in science and technology with our highly diverse group of people having inclusive mind-set.

OUR MISSION

We create antibody drug clinical candidates using our proprietary antibody engineering technology platforms, and support drug development towards clinical development.

We identify biologically active cyclic peptide binders using our proprietary display technology platforms.

We develop innovative engineering technologies of proteins and cyclic peptides to create drugs even for difficult target molecules.

CORE VALUE

Patient Centric
Make each patient’s well-being our highest priority.

Pioneering Spirit
Pursue innovation by improving ourselves and thinking differently.

Integrity
Maintain the highest standards in all we do to create shared value with society.

Company Profile

Chugai Pharmabody Research (CPR) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd. (“Chugai”), Japan’ s No.1 biopharmaceutical company, a member of Roche group, in January 2012 and started operations on July 2, 2012.

CPR conducts drug discovery research creating new antibody drug clinical candidates focusing on high value First-in-Class and Best-in-Class antibodies for a variety of targets and diseases using our proprietary antibody engineering technologies. CPR also conducts research utilizing our cyclic peptide drug discovery platform.

Company Name

Chugai Pharmabody Research Pte. Ltd.
(“Pharmabody” is coined from the words pharmaceutical and antibody.)

Establishment

January 10, 2012

Location

3 Biopolis Drive, #07–11 to 16 Synapse, Singapore 138623

Commencement of Operations

July 2, 2012

Capital

S$ 1.5 million

CEO

Hideaki Shimada Ph.D.

Shareholder

Wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd.

Board of Directors

Sir David Lane, Chairman of the Board

Hideaki Shimada, Director and CEO
Hisafumi Yamada, Director
Arnold Levine, Director

Number of Employees

138 (as of 3 Jan 2022)

History

“”

1925

Juzo Ueno founded Chugai Shinkyaku Co., Ltd. and began the import and sale of medicinal drugs.

“”

1943

Reorganized into a corporation and company name changed to Chugai Pharmaceutical Co., Ltd. (Photo of Matsunage Plant)

“”

2002

Announcement of the strategic alliance with Roche and started business with Roche.

“”

2012

Established Chugai Pharmabody Research Pte. Ltd. In Singapore

“”

2018

Announcement of Business Expansion of Chugai Pharmabody Research Pte. Ltd.

Sir David Lane

Chairman of the Board

With its proprietary antibody engineering and cyclic peptide research technologies, CPR has great potential to create a world-leading technology platform that transforms the efficacy of antibody and cyclic-based drugs. At the same time, CPR can leverage on this technology to contribute to a community of innovation. Since its establishment, CPR has increasingly embedded itself into Singapore’s vibrant research scene through its research performance and involvement in external activities such as the organisation of antibody symposiums. As a result, expectations from others have also been increasing. I am very proud to help CPR generate a pipeline of innovative products that will help patients around the world. I am also pleased to help CPR foster closer interactions with Singapore’s international research community.

Meet Our Directors

DR HISAFUMI YAMADA

Director

Since its inception, CPR has made significant achievements in drug discovery. Utilising Chugai’s proprietary antibody technologies to create high-quality antibody drug candidates, CPR has been able to bring promising discoveries to the proof-of-concept stage in clinical development. With expanding capacity, CPR has stepped up its development of novel antibody technologies, driving innovative efforts in new clinical areas. CPR is also a model of diversity and inclusion within the Chugai Group, drawing from the perspectives and cross-disciplinary expertise from the different nationalities working in CPR. I believe that CPR’s continued pursuit of innovation will lead to better treatments and improved patient health. This will bring us one step closer to realising Chugai’s vision of becoming a leading global innovator within the healthcare industry.

CPR has carved out a unique niche for itself in the pharmaceutical and biotech industry. It has devoted significant time and resources to develop original classes of technologies. This includes research into monoclonal antibodies that are able to enhance half-lives and permit selectivity of target cells in the body, as well as bi- and tri-specific antibodies connecting cells in vivo to enhance immunity. CPR is also intensifying research into innovative cyclic peptides to probe protein-protein interactions and produce new classes of drugs. On the frontier of novel research, CPR is pioneering game-changing technologies and exploring new spaces so it can make a meaningful impact on the health of patients. This is the future!

Dr Arnold Levine

Director

CPR has carved out a unique niche for itself in the pharmaceutical and biotech industry. It has devoted significant time and resources to develop original classes of technologies. This includes research into monoclonal antibodies that are able to enhance half-lives and permit selectivity of target cells in the body, as well as bi- and tri-specific antibodies connecting cells in vivo to enhance immunity. CPR is also intensifying research into innovative cyclic peptides to probe protein-protein interactions and produce new classes of drugs. On the frontier of novel research, CPR is pioneering game-changing technologies and exploring new spaces so it can make a meaningful impact on the health of patients. This is the future!